Akèy › Kansè Poumon ki pa ti selil › Alabama › Birmingham
Etid klinik pou Kansè Poumon ki pa ti selil nan Birmingham, AL
22 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Birmingham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Ap rekriteFaz 3
- Central Alabama Research ( Site 0108), Birmingham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Ap rekriteFaz 3
- Alabama Oncology, Birmingham
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Alabama Oncology, St Vincent's Birmingham, Birmingham
- Alabama Oncology, Brookwood, Birmingham
- Alabama Oncology, Princeton, Birmingham
- ak 5 plis
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
Pan-tumor MRD Study
Ap rekriteEtid obsèvasyon
- Alabama Oncology, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Alabama at Birmingham, Birmingham
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Ap rekriteFaz 2/3
- Birmingham Hematology and Oncology Associates LLC d/b/a Alabama Oncology, Birmingham
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Ap rekriteFaz 1/2
- UAB Medicine - UAB Hospital, Birmingham
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Ap rekriteFaz 3
- Local Institution - 0347, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- The University of Alabama, Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- University of Alabama at Birmingham, Birmingham
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Ap rekriteFaz 1/2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
Ap rekriteFaz 1
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Uni of Alabama at Birmingham, Birmingham
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Alabama at Birmingham, Birmingham
- University of Alabama at Birmingham, IDS Pharmacy, Birmingham
- University of Alabama at Birmingham, Birmingham
- ak 1 plis
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- Central Alabama Research, Birmingham
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Ap rekriteFaz 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- University of Alabama at Birmingham, Birmingham
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Ap rekriteFaz 2
- The University of Alabama at Birmingham Hospital, Birmingham
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Alabama Oncology, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Birmingham
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Birmingham
- Kansè (tout kalite)30 etid
- Kansè nan tete24 etid
- Obèsite23 etid
- Kansè ovè23 etid
- Leksemi mieloïd egi21 etid
- Myelom Miltip18 etid
- BPCO17 etid
- Maladi kadyovaskilè17 etid
- Sipwa16 etid
- Kansè Endomèt16 etid
- Dyabèt Tip 216 etid
- Fibroz sistik16 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.